W
WAVEMAN · COMPANY
NRIX · Nurix Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

NRIX

Nurix Therapeutics, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001549595
FORM 144 · 8☆ WATCH
INSIDER NET · 180D
-$3.0M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
111
13F, latest reported quarter
REVENUE GROWTH
+54.0%
XBRL, annual
NET MARGIN
-314.9%
CONVERSIONS · 180D
27
codes C/M, not in net · $411.1K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$3.0M over 180 days
-$2.1M over 90 days
below 73% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
111 funds added or opened last quarter
more than 69% of Pharma & Biotech
REVENUE
+54.0% year over year
more than 80% of Pharma & Biotech
MARGIN
-314.9% net margin
below 78% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
17.7% of shares outstanding short · 18.0 days to cover · settled 2026-07-31
more than 93% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$3.0M across 3 people in 180 days.
111 funds added or opened positions in the latest 13F quarter, of 214 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +186.9%
+186.9%12M
-10%+62%+134%+205%2025-092025-102025-122026-032026-052026-072026-09 2025-11-24 · Ring Christine sold $641.8K2026-06-25 · Ring Christine sold $580.4K2026-08-03 · Ring Christine sold $382.4K2026-07-02 · Ring Christine sold $259.4K2026-02-09 · Ring Christine sold $237.6K2026-05-05 · van Houte Hans sold $223.4K2026-09-02 · Ring Christine sold $138.4K2026-05-04 · Ring Christine sold $138.2K2026-06-02 · Ring Christine sold $135.3K2026-03-02 · Ring Christine sold $125.8K2026-04-02 · Ring Christine sold $124.2K2026-08-05 · Hansen Gwenn sold $108.9K2026-06-25 · Hansen Gwenn sold $107.9K2026-05-01 · Ring Christine sold $90.4K2026-07-30 · Hansen Gwenn sold $90.0K2026-07-30 · Ring Christine sold $90.0K2026-01-30 · Hansen Gwenn sold $79.5K2025-11-03 · van Houte Hans sold $78.9K2026-08-04 · van Houte Hans sold $73.1K2026-01-30 · Ring Christine sold $71.8K2026-01-20 · Ring Christine sold $69.3K2026-07-30 · van Houte Hans sold $66.5K2026-08-04 · Hansen Gwenn sold $64.3K2025-12-18 · Ring Christine sold $63.6K2026-01-30 · van Houte Hans sold $59.5K2026-04-30 · Ring Christine sold $53.5K2026-04-30 · Hansen Gwenn sold $53.5K2025-10-30 · Hansen Gwenn sold $52.3K2025-10-30 · Ring Christine sold $46.6K2026-08-04 · van Houte Hans sold $42.9K2025-10-30 · van Houte Hans sold $40.1K2026-04-30 · van Houte Hans sold $39.8K2026-09-01 · Hansen Gwenn sold $37.0K2026-08-04 · Hansen Gwenn sold $35.8K2026-09-02 · Ring Christine sold $10.7K2026-05-05 · van Houte Hans sold $10.0K2025-12-18 · Ring Christine sold $3.7K2026-01-30 · Hansen Gwenn sold $1.7K2026-01-30 · Ring Christine sold $1.5K2026-01-30 · van Houte Hans sold $1.3K2026-09-02 · CHRISTINE RING filed to sell $150.7K2026-08-05 · GWENN HANSEN filed to sell $215.1K2026-08-04 · GWENN M HANSEN filed to sell $95.5K2026-08-04 · JOHANNES VAN HOUTE filed to sell $110.6K2026-08-03 · CHRISTINE RING filed to sell $385.0K2026-07-02 · CHRISTINE RING filed to sell $263.2K2026-06-25 · GWENN M HANSEN filed to sell $104.1K2026-06-25 · CHRISTINE RING filed to sell $558.4K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $3.0M sold by insiders over 180 days, 111 funds added last quarter, $1.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Nurix Therapeutics, Inc. insiders sold a net $3.0M of stock across 147 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Ring Christine
Chief Legal Officer
SELL
2026-09-02
5,387.0
$138.4K
Ring Christine
Chief Legal Officer
SELL
2026-09-02
400.0
$10.7K
Hansen Gwenn
Chief Scientific Officer
SELL
2026-09-01
1,452.0
$37.0K
Hansen Gwenn
Chief Scientific Officer
SELL
2026-08-05
4,356.0
$108.9K
van Houte Hans
Chief Financial Officer
SELL
2026-08-04
1,794.0
$42.9K
147 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 142 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
8,770,349.0 sh
$212.8M
Vestal Point Capital, LP
8,050,000.0 sh
$195.3M
Deep Track Capital, LP
7,736,455.0 sh
$187.7M
Rubric Capital Management LP
7,227,778.0 sh
$175.3M
FMR LLC
5,485,215.0 sh
$133.1M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
CHRISTINE RING
FILED 2026-09-02
$150.7K
GWENN HANSEN
FILED 2026-08-05
$215.1K
GWENN M HANSEN
FILED 2026-08-04
$95.5K
JOHANNES VAN HOUTE
FILED 2026-08-04
$110.6K
CHRISTINE RING
FILED 2026-08-03
$385.0K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
ARK Genomic Revolution ETF
$28.8M POSITION · AS OF 2026-04-30
2.3%
Eventide Healthcare & Life Sciences Fund
$20.1M POSITION · AS OF 2026-03-31
1.3%
Global X HealthTech ETF
$416.7K POSITION · AS OF 2026-02-28
1.2%
AlphaCentric Life Sciences and Healthcare Fund
$396.4K POSITION · AS OF 2026-03-31
1.0%
Tema Oncology ETF
$1.6M POSITION · AS OF 2026-02-28
1.0%
Virtus Biotech Clinical Trials Etf
$241.7K POSITION · AS OF 2026-04-30
0.6%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 10 registered trials, 6 still enrolling or running — a status change here is dated weeks before the press release
7
Phase 1
3 ACTIVE
1
Phase 2
1 ACTIVE
1
Phase 3
1 ACTIVE
1
Multi-phase
1 ACTIVE
What changed recently
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
2026-09-01 · Not Yet Recruiting → Recruiting
Phase 3
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-112024-112023-112022-11
REVENUE$84.0M$54.5M$77.0M$38.6M
OPERATING INCOME$-285.7M$-213.0M$-155.1M$-183.9M
NET INCOME$-264.5M$-193.6M$-143.9M$-180.4M
EPS (DILUTED)-3.05-2.88-2.65-3.71
OPERATING CASH FLOW$-249.5M$-172.6M$-81.4M$-159.8M
CASH$247.0M$110.0M$54.6M$64.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →